Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

[1]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.

[2]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[3]  Steven H. Liang,et al.  Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. , 2016, Angewandte Chemie.

[4]  D. Costa.  ALK inhibitors: plateauing systemic and intracranial activity? , 2016, The Lancet Oncology.

[5]  D. Costa,et al.  Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches , 2016, Therapeutic advances in respiratory disease.

[6]  Steven H. Liang,et al.  Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(iii) ylides , 2016, Chemical science.

[7]  N. Sach,et al.  Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners. , 2016, Angewandte Chemie.

[8]  D. Planchard,et al.  ALK inhibitors in non-small cell lung cancer: the latest evidence and developments , 2016, Therapeutic advances in medical oncology.

[9]  R. Schirrmacher,et al.  Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging , 2015, Molecules.

[10]  Akira Inoue,et al.  Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? , 2015, Anticancer research.

[11]  K. Varnäs,et al.  Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. , 2015, Journal of medicinal chemistry.

[12]  C. Lovly,et al.  Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer , 2015, Cancer journal.

[13]  Shibing Deng,et al.  PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. , 2015, Cancer cell.

[14]  G. Toyokawa,et al.  Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data , 2015, Oncology Research and Treatment.

[15]  M. McTigue,et al.  PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations , 2015, Proceedings of the National Academy of Sciences.

[16]  Steven H. Liang,et al.  Iodonium Ylide–Mediated Radiofluorination of 18F-FPEB and Validation for Human Use , 2015, The Journal of Nuclear Medicine.

[17]  V. Mittal,et al.  Novel ALK inhibitors in clinical use and development , 2015, Journal of Hematology & Oncology.

[18]  S. Ou,et al.  Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. , 2015, Chinese clinical oncology.

[19]  Meining Wang,et al.  Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance , 2015, Acta pharmaceutica Sinica. B.

[20]  S. Yamazaki,et al.  Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase AUTHORS: , 2014 .

[21]  Andrei K. Yudin,et al.  Macrocycles: lessons from the distant past, recent developments, and future directions , 2014, Chemical science.

[22]  Giancarlo Pascali,et al.  Optimization of nucleophilic 18F radiofluorinations using a microfluidic reaction approach , 2014, Nature Protocols.

[23]  M. Ceccon.  Ceritinib as a promising therapy for ALK related diseases. , 2014, Translational lung cancer research.

[24]  Wei Liu,et al.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.

[25]  Huichun Zhu,et al.  Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant , 2014 .

[26]  Steven H. Liang,et al.  Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics , 2014, Nature Communications.

[27]  Steven H. Liang,et al.  Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. , 2014, Journal of labelled compounds & radiopharmaceuticals.

[28]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive , 2014, Clinical Cancer Research.

[29]  H. Ohno,et al.  Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction. , 2014, Journal of clinical and experimental hematopathology : JCEH.

[30]  P. Cumming,et al.  PET radiopharmaceuticals for probing enzymes in the brain. , 2013, American journal of nuclear medicine and molecular imaging.

[31]  F. Hirsch,et al.  The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer , 2013, Current opinion in oncology.

[32]  W. Wadsak,et al.  Radiolabeling of [18F]altanserin - a microfluidic approach. , 2012, Nuclear medicine and biology.

[33]  P. Cumming,et al.  PET of Signal Transduction Pathways in Cancer , 2012, The Journal of Nuclear Medicine.

[34]  Robert B. Innis,et al.  Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  J. Llop,et al.  Fully automated and reproducible radiosynthesis of high specific activity [11C]raclopride and [11C]Pittsburgh compound-B using the combination of two commercial synthesizers , 2011, Nuclear medicine communications.

[36]  W. Wadsak,et al.  Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11C]methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB). , 2011, Applied Radiation and Isotopes.

[37]  S. Kobayashi,et al.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Alan A. Wilson,et al.  Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT , 2010, Molecules.

[39]  F. Kelleher,et al.  The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. , 2010, European journal of cancer.

[40]  Petr Znamenskiy,et al.  Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications , 2008, Neuropsychopharmacology.

[41]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  Michael G Stabin,et al.  PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT , 2003, Health physics.

[43]  Matthew J. McAuliffe,et al.  Medical Image Processing, Analysis and Visualization in clinical research , 2001, Proceedings 14th IEEE Symposium on Computer-Based Medical Systems. CBMS 2001.

[44]  J. Chan,et al.  TIMELY TOPIC: ANAPLASTIC LYMPHOMA KINASE (ALK) SPREADS ITS INFLUENCE , 2001, Pathology.

[45]  Alan A. Wilson,et al.  Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. , 2000, Nuclear medicine and biology.

[46]  D M Foster,et al.  Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. , 1998, Advances in experimental medicine and biology.

[47]  L. Deady,et al.  Relative rates of N-methylation of o-substituted pyridines. Steric and electronic effects , 1972 .